

Preeclampsia sFlt-1/PIGF ratio

Short-term prediction and diagnosis of preeclampsia

Determination of the sFlt-1/PIGF ratio **from gestational week 20+0**

Suggested patient profile

1 Investigation of suspected preeclampsia

OR

- 2** One of the following risk factors
- Preeclampsia in a previous pregnancy
 - Preexisting hypertension
 - Preexisting kidney disease
 - Preexisting diabetes

Sample material: **blood serum**

Early-onset preeclampsia

gestational weeks 20 – 33 + 6 days

sFlt-1/PIGF ≥ 85	▶	Diagnosis	▶	99.5 % specificity the woman has preeclampsia Sensitivity: 88.0 %
sFlt-1/PIGF < 85 ≥ 38	▶	Prediction rule-in within next 4 weeks	▶	38.6 % PPV the woman is at high risk to develop preeclampsia within the next 4 weeks
sFlt-1/PIGF < 38	▶	Prediction rule-out for the next 1 week	▶	99.1 % NPV the woman will not develop preeclampsia for the next 1 week

Late-onset preeclampsia

gestational week 34 to end of pregnancy

sFlt-1/PIGF ≥ 110	▶	Diagnosis	▶	95.5 % specificity the woman has preeclampsia Sensitivity: 58.2 %
sFlt-1/PIGF < 110 ≥ 38	▶	Prediction rule-in within next 4 weeks	▶	38.6 % PPV the woman is at high risk to develop preeclampsia within the next 4 weeks
sFlt-1/PIGF < 38	▶	Prediction rule-out for the next 1 week	▶	99.1 % NPV the woman will not develop preeclampsia for the next 1 week

References

- Verlohren, S., Galindo, A., Schlembach, D., Zeisler, H., Herraiz, I., et al. (2010). An automated method for the determination of the sFit-1/PIGF ratio in the assessment of preeclampsia. *Am J Obstet Gynecol.* 202(2), 161.e1-161.e11.
- Verlohren, S., Herraiz, I., Lapaire, O., Schlembach, D., Zeisler, H., et al. (2014). New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. *Hypertension.* 63(2), 346-52.
- Hund, M., Allegranza, D., Schoedl, M., Dilba, P., Verhagen-Kamerbeek, W., Stepan, H. (2014). Multicenter prospective clinical trial to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): study protocol. *BMC Pregnancy and Childbirth* 14, 324.
- Elecsys® sFit-1 package insert (Nov 2014). Roche Diagnostics Documentation, Basel.
- Elecsys® PIGF package insert (Nov 2014). Roche Diagnostics Documentation, Basel.

COBAS, ELECSYS and LIFE NEEDS ANSWERS are trademarks of Roche.

©2014 Roche · Roche Diagnostics International Ltd · CH-6343 Rotkreuz · Switzerland · www.cobas.com